Which companies are Frontier Biotechnologies's closest peers?

The cockpit's peer set: Shouyao Holdings Beijing (688197.SS), Shaanxi Micot Pharmaceutical Technology (2335.HK), Alphamab Oncology (9966.HK), Sana Biotechnology (SANA), Solid Biosciences (SLDB), Beijing SL Pharmaceutical (002038.SZ), Attovia Therapeutics (ATTO), Anhui Wanbang Pharmaceutical Technology (301520.SZ).

How has Frontier Biotechnologies stock performed?

Over six months to 6 Nov 2026 the shares returned -36.5% against -15.6% for the median peer; over one year -6.2%.

← CockpitCompetitor Analysis › 688221.SS Frontier Biotechnologies Inc. Class AOpen in the cockpit ↗

Frontier Biotechnologies Inc. Class A688221.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Momentum laggard 8

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$746M

US dollars, full cap

Free float

100%

of shares outstanding

$/day

$17.9M

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

-15.2 pp

WACC 11.3%

Hurdle

+22 pp

Req g minus delivered

Next earnings

140 days

26 Mar 2027

Close · CNYCN¥13.28

1D-2.4%

1W+4.4%

1M-16.2%

3M-22.4%

6M-36.5%

YTD-26.4%

1Y-6.2%

ATR %6.2%

52w lowhigh55.7% off high

What Frontier Biotechnologies does

Employees: 314

Frontier Biotechnologies at a glance

Size Frontier Biotechnologies (688221.SS) is a China Health Care company (Biotechnology) with a market value of $746M, the 2922nd largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥13.28 on 6 Nov 2026.

Performance Over six months the shares fell 36.5%, against -15.6% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 20 in its peer set.

Growth Revenue grew 153.4% over the last twelve months (peer median +0.1%); the operating margin is -19.6% (peer median -37.8%).

Valuation It trades at 13.1× enterprise value to sales against a peer median of 4.7× (5th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 43% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 15.2 points below its cost of capital (11.3% WACC).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Frontier Biotechnologies against the median of its 20 peers (local-currency closes).

Frontier Biotechnologies financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥358M	CN¥123M	CN¥129M	CN¥114M	CN¥84.7M
Revenue growth	—	-5%	+13%	+35%	—
Gross profit	CN¥293M	CN¥30.3M	CN¥27.0M	CN¥11.3M	-CN¥9.02M
EBITDA	n/a	-CN¥237M	-CN¥236M	-CN¥297M	-CN¥346M
Net income	-CN¥35.8M	-CN¥268M	-CN¥201M	-CN¥329M	-CN¥357M
Free cash flow	CN¥52.7M	-CN¥244M	-CN¥175M	-CN¥379M	-CN¥409M
Capital expenditure	CN¥11.1M	CN¥29.9M	CN¥18.6M	CN¥129M	CN¥140M
Total debt	CN¥375M	CN¥406M	CN¥407M	CN¥380M	CN¥279M

Quarterly statements and history in the cockpit →

Frontier Biotechnologies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Frontier Biotechnologies is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Frontier Biotechnologies is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Frontier Biotechnologies is the large dot.

Frontier Biotechnologies competitors and peer comparison

How Frontier Biotechnologies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Frontier Biotechnologies against its 20 peers (data as of 6 Nov 2026)
Measure	688221.SS	Peer median	Rank in peer set
1-month return	-16.2%	-8.2%	4th lowest of 21
6-month return	-36.5%	-15.6%	5th lowest of 20
Distance from 52-week high	-55.7%	-41.4%	6th lowest of 21
Revenue growth (TTM)	+153.4%	+0.1%	4th highest of 15
Operating margin	-19.6%	-37.8%	7th highest of 16
EV / Sales	13.1×	4.7×	5th most expensive of 16
Growth the price implies (Req g, 7 yrs)	43.2%	20.1%	2nd most demanding of 6
Growth delivered (Del g)	+21.5%	+11.8%	2nd highest of 6
Hurdle (Req g minus delivered)	+21.7 pp	+8.2 pp	2nd most demanding of 6
ROIC minus cost of capital	-15.2 pp	-13.3 pp	7th lowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
Frontier Biotechnologies 688221.SS	China	$746M	-37%	+153%	-20%	13.1×	43.2%	+21.5%
Shouyao Holdings Beijing 688197.SS	China	$726M	-16%	+4,564%	-92%	43.1×	n/a	n/a
Shaanxi Micot Pharmaceutical Technology 2335.HK	Hong Kong	$777M	n/a	n/a	n/a	n/a	n/a	n/a
Alphamab Oncology 9966.HK	Hong Kong	$777M	-39%	-32%	-38%	8.2×	n/a	n/a
Sana Biotechnology SANA	United States	$709M	-32%	n/a	n/a	n/a	n/a	n/a
Solid Biosciences SLDB	United States	$707M	-9%	n/a	n/a	n/a	n/a	n/a
Beijing SL Pharmaceutical 002038.SZ	China	$793M	-21%	-4%	-119%	7.6×	-12.3%	-10.9%
Attovia Therapeutics ATTO	United States	$697M	+744%	n/a	-4,975%	625.6×	n/a	n/a
Anhui Wanbang Pharmaceutical Technology 301520.SZ	China	$803M	+91%	-15%	-8%	17.9×	48.8%	+14.7%
R&G PharmaStudies 301333.SZ	China	$803M	-12%	+21%	11%	3.9×	20.1%	+11.8%
Anhui Huaheng Biotechnology 688639.SS	China	$688M	-40%	+7%	3%	2.1×	n/a	n/a
Wuhan Keqian Biology 688526.SS	China	$814M	-19%	-22%	20%	4.7×	8.8%	+2.4%
Shenzhen Weiguang Biological Products 002880.SZ	China	$682M	-22%	0%	18%	4.7×	n/a	n/a
Aura Biosciences AURA	United States	$680M	-22%	n/a	n/a	n/a	n/a	n/a
4D Molecular Therapeutics FDMT	United States	$677M	+21%	+278,712%	-214%	3.9×	n/a	n/a
Candel Therapeutics CADL	United States	$670M	+5%	n/a	n/a	n/a	n/a	n/a
Boji Medical Technology 300404.SZ	China	$664M	+7%	+32%	4%	4.1×	35.4%	+27.2%
Wave Life Sciences WVE	United States	$664M	-53%	-35%	-321%	3.9×	n/a	n/a
Prime Medicine PRME	United States	$843M	+45%	-18%	-4,825%	211.3×	n/a	n/a
Peptidream 4587.T	Japan	$856M	-10%	+1%	-25%	6.6×	n/a	n/a
Syndax Pharmaceuticals SNDX	United States	$859M	-56%	+160%	-62%	3.5×	n/a	n/a

Questions

Which companies are Frontier Biotechnologies's closest peers?: The cockpit's peer set: Shouyao Holdings Beijing (688197.SS), Shaanxi Micot Pharmaceutical Technology (2335.HK), Alphamab Oncology (9966.HK), Sana Biotechnology (SANA), Solid Biosciences (SLDB), Beijing SL Pharmaceutical (002038.SZ), Attovia Therapeutics (ATTO), Anhui Wanbang Pharmaceutical Technology (301520.SZ).
Is Frontier Biotechnologies expensive compared with its peers?: On ev / sales it trades at 13.1× against a peer median of 4.7×, 5th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 43% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is +22 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Frontier Biotechnologies stock performed?: Over six months to 6 Nov 2026 the shares returned -36.5% against -15.6% for the median peer; over one year -6.2%.